Zobrazeno 1 - 10
of 17 790
pro vyhledávání: ''
Autor:
Ulrich Gatzemeier, Michael Boyer, Paolo Paoletti, Salih Emri, Christian Manegold, Claude Denham, Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski, Clet Niyikiza, E. Kaukel, Pierre Ruffié
Publikováno v:
Journal of Clinical Oncology. 41:2125-2133
PURPOSE Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy. We conducted a phase III trial to determine whether treatment with
Autor:
Charles L, Vogel, Melody A, Cobleigh, Debu, Tripathy, John C, Gutheil, Lyndsay N, Harris, Louis, Fehrenbacher, Dennis J, Slamon, Maureen, Murphy, William F, Novotny, Michael, Burchmore, Steven, Shak, Stanford J, Stewart, Michael, Press
Publikováno v:
Journal of Clinical Oncology. 41:1638-1645
PURPOSE To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer. PATIENTS AND METHODS One hundred fourteen women with HER2-overexpressing metastatic breast cancer were ran
Autor:
Lalit Kumar, Mohammad Mir Hussain, Rajegowda Chethan, Ranjit Kumar Sahoo, Prabhat S. Malik, Om Dutt Sharma, Anisha Mathew, Ankit Jha, Ritu Gupta, Atul Sharma, Ahitagni Biswas, Rakesh Kumar, Sanjay Thulkar, Soumyaranjan Malik, Ashish Dutt
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:e826-e835
Autologous stem cell transplant (ASCT) is a standard therapy for transplant eligible patients of multiple myeloma (MM). To evaluate impact of time to transplant on subsequent outcomes, we analyzed data on consecutive MM patients who received novel ag
Publikováno v:
Breast Cancer Research and Treatment. 194:507-516
To compare the outcome of allogeneic stem cell transplantation for myeloid malignancies in breast cancer survivors to a contemporaneous control group.Medical records of all patients with a history of breast cancer who received allogeneic stem cell tr
Autor:
Samia Hajar Touimi, Noureddine Benjaafar, I Mbarki, Tayeb Kebdani, Patricia Agbanglanon, Norosoa Randriamarosona, Sanaa Elmajjaoui, Hanan Elkacemi
Publikováno v:
Bulletin du Cancer. 109:280-286
Summary Objective Radiotherapy remains an essential part of the management of locally advanced cervical cancer. Post-treatment surveillance allows for tumor response assessment and early detection of progressive prosecutions or local recurrences that
Autor:
Yoshihiro, Araki, Norio, Yamamoto, Toru, Maeda, Hiroaki, Kimura, Takashi, Ota, Shingo, Shimozaki, Takashi, Kato, Daisuke, Inoue, Takashi, Higuchi, Kensaku, Abe, Yuta, Taniguchi, Hiroyuki, Tsuchiya
Publikováno v:
Anticancer Research. 42:1555-1562
The management of soft-tissue tumors of 2-5 cm is not specified. We investigated the management of these cases.Among 105 cases with soft-tissue tumors from 2014 to 2021, 38 with tumors of 2-5 cm were retrospectively reviewed. The clinical characteris
Autor:
Yasuro, Futagawa, Shinji, Onda, Shuichi, Fujioka, Teruyuki, Usuba, Yukio, Nakabayashi, Takeyuki, Misawa, Tomoyoshi, Okamoto, Toru, Ikegami
Publikováno v:
Anticancer Research. 42:1579-1588
Management strategies for pseudoaneurysm rupture after pancreatic resection have not yet been firmly established due to its low incidence and effects of environmental variability among centers. This study aimed to provide a basis for treatment strate
Autor:
Shota, Ike, Masatake, Matsuoka, Tomohiro, Onodera, Isao, Yokota, Koji, Iwasaki, Ryosuke, Hishimura, Yuki, Suzuki, Eiji, Kondo, Norimasa, Iwasaki
Publikováno v:
Anticancer Research. 42:1635-1640
Primary malignant osseous neoplasms of the hand are rare malignancies. Comprehensive demographic and survival data regarding primary malignant osseous neoplasms of the hand are lacking in the literature.Using the Surveillance, Epidemiology, and End R
Autor:
Sari, Jaamaa, Riikka, Nevala, Kiran, Jagarlamudi, Erkki, Tukiainen, Carl, Blomqvist, Mika, Sampo
Publikováno v:
Anticancer Research. 42:1509-1515
The aim of this prospective study was to determine whether serum Thymidine kinase -1 (TK1) could serve as a tumor marker in soft tissue sarcomas (STS).A total of 48 patients diagnosed with localized STS were included. None had received preoperative o
Autor:
Lihua E. Budde, Sarit Assouline, Laurie H. Sehn, Stephen J. Schuster, Sung-Soo Yoon, Dok Hyun Yoon, Matthew J. Matasar, Francesc Bosch, Won Seog Kim, Loretta J. Nastoupil, Ian W. Flinn, Mazyar Shadman, Catherine Diefenbach, Carol O'Hear, Huang Huang, Antonia Kwan, Chi-Chung Li, Emily C. Piccione, Michael C. Wei, Shen Yin, Nancy L. Bartlett
Publikováno v:
Scientia
PURPOSE Mosunetuzumab is a bispecific antibody targeting CD20 and CD3 that redirects T cells to engage and eliminate malignant B cells and is being developed for relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs). METHODS This first-i